Key result
Enhanced sampling simulations revealed that most of the nine tested sodium channel inhibitors share a common, highly promiscuous binding location near the mouth of the DII-III fenestration.
Why the study?
Specific knowledge of protein-drug interactions and subtle structural variations among small molecule sodium channel inhibitors used in cardiac and nervous system pathologies was lacking.
Computational simulations reveal that sodium channel inhibitors exhibit polyspecific and diffuse binding within the Nav1.5 pore, providing insights for future antiarrhythmic drug design.
Does not support changing antiarrhythmic use; leaves open fenestration-specific modeling for selective inhibitors.
Small molecule inhibitors of the sodium channel are common pharmacological agents used to treat a variety of cardiac and nervous system pathologies. They act on the channel via binding within the pore to directly block the sodium conduction pathway and/or modulate the channel to favor a non-conductive state. Despite their abundant clinical use, we lack specific knowledge of their protein-drug interactions and the subtle variations between different compound structures. This study investigates the binding and accessibility of nine different compounds in the pore cavity of the Nav1.5 sodium channel using enhanced sampling simulations. We find that most compounds share a common location of pore binding-near the mouth of the DII-III fenestration-associated with the high number of aromatic residues in this region. In contrast, some other compounds prefer binding within the lateral fenestrations where they compete with lipids, rather than binding in the central cavity. Overall, our simulation results suggest that the drug binding within the pore is highly promiscuous, with most drugs having multiple low-affinity binding sites. Access to the pore interior via two out of four of the hydrophobic fenestrations is favorable for the majority of compounds. Our results indicate that the polyspecific and diffuse binding of inhibitors in the pore contributes to the varied nature of their inhibitory effects and can be exploited for future drug discovery and optimization.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2024) studied this question. Small molecule inhibitors was evaluated on Binding and accessibility in the pore cavity of the Nav1.5 sodium channel. Enhanced sampling simulations revealed that most of the nine tested sodium channel inhibitors share a common, highly promiscuous binding location near the mouth of the DII-III fenestration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: